Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,934 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Röth A, Broome CM, Barcellini W, Jilma B, Hill QA, Cella D, Tvedt THA, Yamaguchi M, Lee M, Shafer F, Wardęcki M, Jiang X, Patel P, Joly F, Weitz IC. Röth A, et al. Among authors: yamaguchi m. Eur J Haematol. 2023 Mar;110(3):280-288. doi: 10.1111/ejh.13903. Epub 2022 Dec 9. Eur J Haematol. 2023. PMID: 36403132 Clinical Trial.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Among authors: yamaguchi m. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Human herpesvirus-8-unrelated primary effusion lymphoma of the elderly not associated with an increased serum lactate dehydrogenase level: A benign sub-group of effusion lymphoma without chemotherapy.
Zaimoku Y, Takahashi W, Iwaki N, Saito C, Yoshida A, Aoki G, Yamaguchi M, Nakao S. Zaimoku Y, et al. Among authors: yamaguchi m. Leuk Lymphoma. 2016 Jul;57(7):1625-32. doi: 10.3109/10428194.2015.1088649. Epub 2016 Jan 4. Leuk Lymphoma. 2016. PMID: 26727336 Review.
Osteosarcoma Manifesting Systemic Inflammation and Histological Features Mimicking Plasma Cell-type Castleman Disease.
Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Doai M, Matoba M, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Mizumaki H, Yamaguchi M, Masaki Y. Fujimoto S, et al. Among authors: yamaguchi m. Intern Med. 2019 Sep 1;58(17):2555-2560. doi: 10.2169/internalmedicine.2738-19. Epub 2019 Jun 7. Intern Med. 2019. PMID: 31178507 Free PMC article.
Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.
Kiguchi T, Yamaguchi M, Takezako N, Miyawaki S, Masui K, Ihara Y, Hirota M, Shimofurutani N, Naoe T. Kiguchi T, et al. Among authors: yamaguchi m. Cancer Immunol Immunother. 2022 Jun;71(6):1419-1430. doi: 10.1007/s00262-021-03074-4. Epub 2021 Oct 22. Cancer Immunol Immunother. 2022. PMID: 34677647 Free PMC article. Clinical Trial.
5,934 results